Depression and synaptic zinc regulation in alzheimer disease, dementia with lewy bodies, and parkinson disease dementia

American Journal of Geriatric Psychiatry

Volumn 23, Issue 2, 2015, Pages 141-148

  Whitfield, David R ^a   Vallortigara, Julie ^a   Alghamdi, Amani ^a,b   Hortobágyi, Tibor ^c   Ballard, Clive ^a   Thomas, Alan J ^d   O'Brien, John T ^e   Aarsland, Dag ^f,g   Francis, Paul T ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b KING SAUD UNIVERSITY   (Saudi Arabia)

^c UNIVERSITY OF DEBRECEN   (Hungary)

^d NEWCASTLE UNIVERSITY   (United Kingdom)

^e UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^f KAROLINSKA INSTITUTE   (Sweden)

^g STAVANGER UNIVERSITY HOSPITAL   (Norway)

Author keywords

Alzheimer disease; Depression; Lewy body dementia; Parkinson disease dementia; zinc

Indexed keywords

BETA TUBULIN; UNCLASSIFIED DRUG; ZINC; ZINC TRANSPORTER; ZINC TRANSPORTER 3; CATION TRANSPORT PROTEIN; SLC30A3 PROTEIN, HUMAN;

AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN; CINGULATE GYRUS; CONTROLLED STUDY; DEPRESSION; DIFFUSE LEWY BODY DISEASE; DISEASE ASSOCIATION; FEMALE; FRONTAL CORTEX; GRAY MATTER; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; MONTGOMERY ASBERG DEPRESSION RATING SCALE; PARIETAL CORTEX; PARKINSON DISEASE; PREFRONTAL CORTEX; WESTERN BLOTTING; CASE CONTROL STUDY; COMPLICATION; FRONTAL LOBE; METABOLISM; PARIETAL LOBE; SYNAPSE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; CASE-CONTROL STUDIES; CATION TRANSPORT PROTEINS; DEPRESSION; FEMALE; FRONTAL LOBE; GYRUS CINGULI; HUMANS; LEWY BODY DISEASE; MALE; PARIETAL LOBE; PARKINSON DISEASE; SYNAPSES; ZINC;

EID: 84928012557     PISSN: 10647481     EISSN: 15457214     Source Type: Journal    
DOI: 10.1016/j.jagp.2014.05.001     Document Type: Article

References (38)

1. Fritze F, Ehrt U, Sønnesyn H, et al: Depression in mild dementia: associations with diagnosis, APOE genotype and clinical features. Int J Geriatr Psychiatry 2011; 26:1054-1061
2. Fritze F, Ehrt U, Hortobagyi T, et al: Depressive symptoms in Alzheimer's disease and Lewy body dementia: a one-year followup study. Dement Geriatr Cogn Disord 2011; 32:143-149
3. Byers AL, Yaffe K: Depression and risk of developing dementia. Nat Rev Neurol 2011; 7:323-331
4. Gracia-García P, de-la-Cámara C, Santabárbara J, et al: Depression and incident Alzheimer disease: the impact of disease severity. Am J Geriatr Psychiatry 2015; 23:119-129
5. Köhler S, van Boxtel M, Jolles J, et al: Depressive symptoms and risk for dementia: a 9-year follow-up of the Maastricht Aging Study. Am J Geriatr Psychiatry 2011; 19:902-905
6. Munro CA, Longmire CF, Drye LT, et al: Cognitive outcomes after sertaline treatment in patients with depression of Alzheimer disease. Am J Geriatr Psychiatry 2012; 20:1036-1044
7. Bains J, Birks JS, Dening TR: The efficacy of antidepressants in the treatment of depression in dementia. Cochrane Database Syst Rev 2002:CD003944
8. Weintraub D, Rosenberg PB, Drye LT, et al: Sertraline for the treatment of depression in Alzheimer disease: weeke24 outcomes. Am J Geriatr Psychiatry 2010; 18:332-340
9. Banerjee S, Hellier J, Dewey M, et al: Sertraline or mirtazapine for depression in dementia (HTA-SADD): a randomised, multicentre, double-blind, placebo-controlled trial. Lancet 2011; 378: 403-411
10. Banerjee S, Hellier J, Romeo R, et al: Study of the use of antidepressants for depression in dementia: the HTA-SADD trial-A multicentre, randomised, double-blind, placebo-controlled trial of the clinical effectiveness and cost-effectiveness of sertraline and mirtazapine. Health Technol Assess 2013; 17:1-166
11. Aarsland D, Pahlhagen S, Ballard CG, et al: Depression in Parkinson disease-epidemiology, mechanisms and management. Nat Rev Neurol 2012; 8:35-47
12. Sensi SL, Paoletti P, Bush AI, et al: Zinc in the physiology and pathology of the CNS. Nat Rev Neurosci 2009; 10:780-791
13. Palmiter RD, Cole TB, Quaife CJ, et al: ZnT-3, a putative transporter of zinc into synaptic vesicles. Proc Natl Acad Sci USA 1996; 93:14934-14939
14. Linkous DH, Flinn JM, Koh JY, et al: Evidence that the ZNT3 protein controls the total amount of elemental zinc in synaptic vesicles. J Histochem Cytochem 2008; 56:3-6
15. Cole TB, Wenzel HJ, Kafer KE, et al: Elimination of zinc from synaptic vesicles in the intact mouse brain by disruption of the ZnT3 gene. Proc Natl Acad Sci USA 1999; 96:1716-1721
16. Gundelfinger ED, Boeckers TM, Baron MK, et al: A role for zinc in postsynaptic density asSAMbly and plasticity? Trends Biochem Sci 2006; 31:366-373
17. Swardfager W, Herrmann N, McIntyre RS, et al: Potential roles of zinc in the pathophysiology and treatment of major depressive disorder. Neurosci Biobehav Rev 2013; 37:911-929
18. Nowak G, Schlegel-Zawadzka M: Alterations in serum and brain trace element levels after antidepressant treatment: part I. Zinc. Biol Trace Elem Res 1999; 67:85-92
19. Takeda A, Tamano H, Ogawa T, et al: Significance of serum glucocorticoid and chelatable zinc in depression and cognition in zinc deficiency. Behav Brain Res 2012; 226:259-264
20. Lai J, Moxey A, Nowak G, et al: The efficacy of zinc supplementation in depression: systematic review of randomised controlled trials. J Affect Disord 2012; 136:e31ee39
21. McKeith IG, Dickson DW, Lowe J, et al: Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 2005; 65:1863-1872
22. Khundakar A, Morris C, Oakley A, et al: Morphometric analysis of neuronal and glial cell pathology in the dorsolateral prefrontal cortex in late-life depression. Br J Psychiatry 2009; 195:163-169
23. Khundakar AA, Thomas AJ: Morphometric changes in early-And late-life major depressive disorder: evidence from postmortem studies. Int Psychogeriatr 2009; 21:844-854
24. Yamane Y, Sakai K, Maeda K: Dementia with Lewy bodies is associated with higher scores on the Geriatric Depression Scale than is Alzheimer's disease. Psychogeriatrics 2011; 11:157-165
25. Barnes LL, Wilson RS, Bienias JL, et al: Sex differences in the clinical manifestations of Alzheimer disease pathology. Arch Gen Psychiatry 2005; 62:685-691
26. Rocca WA, Hofman A, Brayne C, et al: Frequency and distribution of Alzheimer's disease in Europe: a collaborative study of 1980-1990 prevalence findings. The EURODEM-Prevalence Research Group. Ann Neurol 1991; 30:381-390
27. Fratiglioni L, Viitanen M, von Strauss E, et al: Very old women at highest risk of dementia and Alzheimer's disease: incidence data from the Kungsholmen Project, Stockholm. Neurology 1997; 48: 132-138
28. Richard E, Reitz C, Honig LH, et al: Late-life depression, mild cognitive impairment, and dementia. JAMA Neurol 2013; 70: 374-382
29. Chen KH, Reese EA, Kim HW, et al: Disturbed neurotransmitter transporter expression in Alzheimer's disease brain. J Alzheim Dis 2011; 26:755-766
30. McLoughlin IJ, Hodge JS: Zinc in depressive disorder. Acta Psychiatr Scand 1990; 82:451-453
31. Szewczyk B, Kubera M, Nowak G: The role of zinc in neurodegenerative inflammatory pathways in depression. Prog Neuropsychopharmacol Biol Psychiatry 2011; 35:693-701
32. Sanacora G, Treccani G, Popoli M: Towards a glutamate hypothesis of depression: an emerging frontier of neuropsychopharmacology for mood disorders. Neuropharmacology 2012; 62:63-77
33. Sharp SI, Ballard CG, Ziabreva I, et al: Cortical serotonin 1A receptor levels are associated with depression in patients with dementia with Lewy bodies and Parkinson's disease dementia. Dement Geriatr Cogn Disord 2008; 26:330-338
34. Tassabehji NM, Corniola RS, Alshingiti A, et al: Zinc deficiency induces depression-like symptoms in adult rats. Physiol Behav 2008; 95:365-369
35. Maes M, Vandoolaeghe E, Neels H, et al: Lower serum zinc in major depression is a sensitive marker of treatment resistance and of the immune/inflammatory response in that illness. Biol Psychiatry 1997; 42:349-358
36. Adlard PA, Cherny RA, Finkelstein DI, et al: Rapid restoration of cognition in Alzheimer's transgenic mice with 8-hydroxy quinoline analogs is associated with decreased interstitial Abeta. Neuron 2008; 59:43-55
37. Crouch PJ, Savva MS, Hung LW, et al: The Alzheimer's therapeutic PBT2 promotes amyloid-beta degradation and GSK3 phosphorylation via a metal chaperone activity. J Neurochem 2011; 119:220-230
38. Lannfelt L, Blennow K, Zetterberg H, et al: Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial. Lancet Neurol 2008; 7:779-786